COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

07/02/2025 - 14:50

Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including [...]

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

07/02/2025 - 15:15

Current Board’s Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months New Leadership is Urgently Needed to Restore Accountability in the Boardroom Restore Value [...]

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

07/02/2025 - 16:00

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) [...]

Carla da Luz Boren Recognized Among Top 50 Women Leaders in Healthcare Technology

07/02/2025 - 16:18

WESTWOOD, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Corza Medical announced that Carla da Luz Boren, J.D., the Company’s chief human resources officer, has been named among the Top 50 Women Leaders in Healthcare [...]

Le CMUH recommande RYBREVANT®▼ (amivantamab) par voie sous-cutanée dans le cadre du traitement des patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR

07/02/2025 - 17:35

Les données issues de l’étude de Phase 3 PALOMA-3 ont révélé une non-infériorité par rapport à l’administration intraveineuse pour les deux co-critères d’évaluation pharmacocinétiques principaux, ainsi qu’une division [...]

OHC - Ford government’s primary care announcement plays politics with people’s need for a family doctor: It’s a primary care “plan” to implement a plan delayed until the cusp of an election

07/02/2025 - 18:44

TORONTO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- No matter how anyone tries to spin the numbers, the actual data from sources not tainted by politics, show that more than a million Ontarians have lost their family doctor [...]

WAKE RADIOLOGY PROMOTES HEART HEALTH WITH ADVANCED IMAGING SERVICES AND SCREENINGS DURING FEBRUARY

07/02/2025 - 18:52

Raleigh, N.C., Feb. 07, 2025 (GLOBE NEWSWIRE) -- This National Wear Red Day, Wake Radiology is raising awareness for heart health by offering advanced cardiac imaging services and encouraging participation in Heart [...]

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

07/02/2025 - 20:56

WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical [...]

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

07/02/2025 - 21:22

BOCA RATON, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non- [...]

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

07/02/2025 - 22:00

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:01

NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:01

WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

07/02/2025 - 22:05

IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar [...]

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:05

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:30

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:30

BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight cancer [...]

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:30

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07/02/2025 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

07/02/2025 - 22:58

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, [...]